Access the full text.
Sign up today, get DeepDyve free for 14 days.
H. Shigematsu, Li Lin, Takao Takahashi, M. Nomura, Makoto Suzuki, I. Wistuba, K. Fong, Hue Lee, S. Toyooka, N. Shimizu, T. Fujisawa, Ziding Feng, J. Roth, J. Herz, J. Minna, A. Gazdar (2006)
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.Journal of the National Cancer Institute, 97 5
Ming-Sound Tsao, Ni Liu, Jim-Ray Chen, Jane Pappas, Joanna Ho, Christine To, Jean Viallet, Morag Park, Hong Zhu (1998)
Differential expression of Met/hepatocyte growth factor receptor in subtypes of non-small cell lung cancers.Lung cancer, 20 1
Jin-Tang Chen, Torng-Sen Lin, K. Chow, Hsuan-hua Huang, S. Chiou, S. Chiang, Hong-Chen Chen, Tzu-Lin Chuang, Tzei-Yi Lin, Chih‐Yi Chen (2006)
Cigarette smoking induces overexpression of hepatocyte growth factor in type II pneumocytes and lung cancer cells.American journal of respiratory cell and molecular biology, 34 3
R. Jagadeeswaran, P. Ma, T. Seiwert, Sujatha Jagadeeswaran, Osvaldo Zumba, V. Nallasura, Salman Ahmed, R. Filiberti, M. Paganuzzi, R. Puntoni, R. Kratzke, G. Gordon, D. Sugarbaker, R. Bueno, Varalakshmi Janamanchi, V. Bindokas, H. Kindler, R. Salgia (2006)
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma.Cancer research, 66 1
Alyssa Bonine-Summers, M. Aakre, K. Brown, C. Arteaga, J. Pietenpol, H. Moses, N. Cheng (2007)
Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cellsCancer Biology & Therapy, 6
G. Rossi, A. Cavazza, A. Marchioni, L. Longo, M. Migaldi, G. Sartori, N. Bigiani, L. Schirosi, C. Casali, U. Morandi, N. Facciolongo, A. Maiorana, M. Bavieri, L. Fabbri, E. Brambilla (2005)
Role of Chemotherapy and the Receptor Tyrosine Kinases KIT, PDGFRα, PDGFRβ, and Met in Large-Cell Neuroendocrine Carcinoma of the LungJournal of Clinical Oncology, 23
T. Shibata, S. Uryu, A. Kokubu, F. Hosoda, M. Ohki, T. Sakiyama, Y. Matsuno, R. Tsuchiya, Y. Kanai, T. Kondo, I. Imoto, J. Inazawa, S. Hirohashi (2005)
Genetic Classification of Lung Adenocarcinoma Based on Array-Based Comparative Genomic Hybridization Analysis: Its Association with Clinicopathologic FeaturesClinical Cancer Research, 11
F. Shepherd, J. Pereira, T. Ciuleanu, E. Tan, V. Hirsh, S. Thongprasert, D. Campos, Savitree Maoleekoonpiroj, M. Smylie, R. Martins, M. Kooten, M. Dediu, B. Findlay, D. Tu, D. Johnston, A. Bezjak, G. Clark, P. Santabarbara, L. Seymour (2005)
Erlotinib in previously treated non-small-cell lung cancer.The New England journal of medicine, 353 2
G. Rossi, A. Cavazza, A. Marchioni, L. Longo, M. Migaldi, G. Sartori, N. Bigiani, L. Schirosi, C. Casali, U. Morandi, N. Facciolongo, A. Maiorana, M. Bavieri, L. Fabbri, E. Brambilla (2005)
Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 34
J. Choi, Long Zheng, E. Ha, Yun Lim, Yeul-Hong Kim, Young-Pil Wang, Young Lim (2006)
Comparative Genomic Hybridization Array Analysis and Real-Time PCR Reveals Genomic Copy Number Alteration for Lung AdenocarcinomasLung, 184
L. Stabile, Jennifer Lyker, S. Land, S. Dacic, B. Zamboni, J. Siegfried (2005)
Transgenic mice overexpressing hepatocyte growth factor in the airways show increased susceptibility to lung cancer.Carcinogenesis, 27 8
T. Kosaka, Y. Yatabe, H. Endoh, H. Kuwano, Takashi Takahashi, T. Mitsudomi (2004)
Mutations of the Epidermal Growth Factor Receptor Gene in Lung CancerCancer Research, 64
M. Tsao, A. Sakurada, J. Cutz, Chang-Qi Zhu, S. Kamel‐Reid, J. Squire, I. Lorimer, Tong Zhang, Ni Liu, M. Daneshmand, P. Marrano, G. Santos, A. Lagarde, F. Richardson, L. Seymour, M. Whitehead, K. Ding, J. Pater, F. Shepherd (2005)
Erlotinib in lung cancer - molecular and clinical predictors of outcome.The New England journal of medicine, 353 2
Yong-Woo Choi, J. Choi, Long Zheng, Yun Lim, H. Yoon, Yeul-Hong Kim, Young-Pil Wang, Young-Hyuck Lim (2007)
Comparative genomic hybridization array analysis and real time PCR reveals genomic alterations in squamous cell carcinomas of the lung.Lung cancer, 55 1
N. Thatcher, A. Chang, P. Parikh, J. Pereira, T. Ciuleanu, J. Pawel, S. Thongprasert, E. Tan, K. Pemberton, V. Archer, K. Carroll (2005)
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)The Lancet, 366
C. Mountain (1997)
Revisions in the International System for Staging Lung Cancer.Chest, 111 6
P. Ma, E. Schaefer, J. Christensen, R. Salgia (2005)
A Selective Small Molecule c-MET Inhibitor, PHA665752, Cooperates with RapamycinClinical Cancer Research, 11
Masaki Tokumo, S. Toyooka, Shuji Ichihara, K. Ohashi, K. Tsukuda, K. Ichimura, M. Tabata, K. Kiura, M. Aoe, Y. Sano, H. Date, N. Shimizu (2006)
Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer.Lung cancer, 53 1
N. Dubrawsky (1989)
Cancer statisticsCA: A Cancer Journal for Clinicians, 39
(2004)
World Health Organization classification of tumours, pathology and genetics: tumours of the lung, pleura, thymus and heart
N. Puri, A. Khramtsov, Salman Ahmed, V. Nallasura, J. Hetzel, R. Jagadeeswaran, G. Karczmar, R. Salgia (2007)
A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.Cancer research, 67 8
E. Ichimura, Arafumi Maeshima, T. Nakajima, Toshikazu Nakamura (1996)
Expression of c‐met/HGF Receptor in Human Non‐small Cell Lung Carcinomas in vitro and in vivo and Its Prognostic SignificanceJapanese Journal of Cancer Research : Gann, 87
T. Ide, Y. Kitajima, Atsushi Miyoshi, T. Ohtsuka, Mayumi Mitsuno, Kazuma Ohtaka, K. Miyazaki (2007)
The Hypoxic Environment in Tumor-Stromal Cells Accelerates Pancreatic Cancer Progression via the Activation of Paracrine Hepatocyte Growth Factor/c-Met SignalingAnnals of Surgical Oncology, 14
G. Maulik, A. Shrikhande, T. Kijima, P. Ma, P. Morrison, R. Salgia (2002)
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition.Cytokine & growth factor reviews, 13 1
M. Myerburg, Joseph Latoche, Erin McKenna, L. Stabile, Jill Siegfried, C. Feghali-Bostwick, J. Pilewski (2007)
Hepatocyte growth factor and other fibroblast secretions modulate the phenotype of human bronchial epithelial cells.American journal of physiology. Lung cellular and molecular physiology, 292 6
M. Wislez, N. Rabbe, J. Marchal, B. Milleron, B. Crestani, C. Mayaud, M. Antoine, P. Soler, J. Cadranel (2003)
Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma: role in tumor progression and death.Cancer research, 63 6
Christine To, I. Seiden, Ni Liu, D. Wigle, M. Tsao (2002)
High expression of Met/hepatocyte growth factor receptor suppresses tumorigenicity in NCI-H1264 lung carcinoma cells.Experimental cell research, 273 1
C. Cooper, Morag Park, D. Blair, M. Tainsky, K. Huebner, C. Croce, G. Woude (1984)
Molecular cloning of a new transforming gene from a chemically transformed human cell lineNature, 311
Yusuke Nakamura, T. Niki, A. Goto, Teppei Morikawa, K. Miyazawa, J. Nakajima, M. Fukayama (2007)
c‐Met activation in lung adenocarcinoma tissues: An immunohistochemical analysisCancer Science, 98
L. Toschi, F. Cappuzzo (2007)
Understanding the new genetics of responsiveness to epidermal growth factor receptor tyrosine kinase inhibitors.The oncologist, 12 2
L. Prudkin, I. Wistuba (2006)
Epidermal growth factor receptor abnormalities in lung cancer. Pathogenetic and clinical implications.Annals of diagnostic pathology, 10 5
M. Kris, R. Natale, R. Herbst, T. Lynch, D. Prager, C. Belani, J. Schiller, K. Kelly, H. Spiridonidis, A. Sandler, K. Albain, D. Cella, M. Wolf, S. Averbuch, J. Ochs, A. Kay (2003)
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.JAMA, 290 16
F. Hirsch, M. Varella-Garcia, P. Bunn, W. Franklin, R. Dziadziuszko, N. Thatcher, A. Chang, P. Parikh, J. Pereira, T. Ciuleanu, J. Pawel, C. Watkins, Angela Flannery, G. Ellison, E. Donald, Lucy Knight, D. Parums, N. Botwood, B. Holloway (2006)
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 31
J. Engelman, K. Zejnullahu, T. Mitsudomi, Youngchul Song, Courtney Hyland, Joon-Oh Park, N. Lindeman, Christopher-Michael Gale, Xiaojun Zhao, J. Christensen, T. Kosaka, A. Holmes, A. Rogers, F. Cappuzzo, T. Mok, Charles Lee, B. Johnson, L. Cantley, P. Jänne (2007)
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 SignalingScience, 316
A. Jemal, R. Siegel, Elizabeth Ward, Taylor Murray, Jiaquan Xu, M. Thun (2007)
Cancer Statistics, 2007CA: A Cancer Journal for Clinicians, 57
C. Birchmeier, W. Birchmeier, E. Gherardi, G. Woude (2003)
Met, metastasis, motility and moreNature Reviews Molecular Cell Biology, 4
M. Beau-Faller, M. Gaub, A. Schneider, E. Guérin, Nicolas Meyer, X. Ducrocq, G. Massard, B. Gasser, R. Kessler, E. Weitzenblum, J. Wihlm, E. Quoix, P. Oudet (2003)
Allelic imbalance at loci containing FGFR, FGF, c-Met and HGF candidate genes in non-small cell lung cancer sub-types, implication for progression.European journal of cancer, 39 17
Gromoslaw Smolen, Raffaella Sordella, B. Muir, G. Mohapatra, A. Barmettler, H. Archibald, Woo-Jin Kim, R. Okimoto, D. Bell, D. Sgroi, J. Christensen, J. Settleman, D. Haber (2006)
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752Proceedings of the National Academy of Sciences of the United States of America, 103
J. Siegfried, J. Luketich, L. Stabile, N. Christie, S. Land (2004)
Elevated hepatocyte growth factor level correlates with poor outcome in early-stage and late-stage adenocarcinoma of the lung.Chest, 125 5 Suppl
M. Fukuoka, S. Yano, G. Giaccone, T. Tamura, K. Nakagawa, J. Douillard, Y. Nishiwaki, J. Vansteenkiste, S. Kudoh, D. Rischin, R. Eek, T. Horai, K. Noda, I. Takata, E. Smit, S. Averbuch, A. Macleod, A. Feyereislova, R. Dong, J. Baselga (2003)
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 21 12
C. Luk, M. Tsao, J. Bayani, F. Shepherd, J. Squire (2001)
Molecular cytogenetic analysis of non-small cell lung carcinoma by spectral karyotyping and comparative genomic hybridization.Cancer genetics and cytogenetics, 125 2
Charles Miller, Lin Lin, A. Casper, J. Lim, Dafydd Thomas, M. Orringer, A. Chang, A. Chambers, T. Giordano, T. Glover, D. Beer (2006)
Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinomaOncogene, 25
B. Lutterbach, Qinwen Zeng, L. Davis, H. Hatch, G. Hang, N. Kohl, J. Gibbs, B. Pan (2007)
Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival.Cancer research, 67 5
D. Bell, T. Lynch, Sara Haserlat, Patricia Harris, R. Okimoto, Brian Brannigan, D. Sgroi, B. Muir, M. Riemenschneider, R. Iacona, A. Krebs, David Johnson, G. Giaccone, R. Herbst, C. Manegold, M. Fukuoka, M. Kris, J. Baselga, J. Ochs, D. Haber (2005)
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 31
ORIGINAL ARTICLE MET Gene Copy Number in Non-small Cell Lung Cancer: Molecular Analysis in a Targeted Tyrosine Kinase Inhibitor Naı¨ve Cohort Miche`le Beau-Faller, MD, PhD,*† Anne-Marie Ruppert, MD,‡ Anne-Claire Voegeli, PD,* Agne`s Neuville, MD,§ Nicolas Meyer, MD, PhD, Eric Guerin, PD, PhD,* Miche`le Legrain, PhD,* Bertrand Mennecier, MD,‡ Jean-Marie Wihlm, MD,¶ Gilbert Massard, MD,¶ Elisabeth Quoix, MD,* Pierre Oudet, MD,*† and Marie P. Gaub, PhD* Conclusion: In EGFR-TKIs naive NSCLC patients, MET amplifi- Introduction: Recent clinical success of epidermal growth factor cation is a frequent event, which could be associated with EGFR (EGFR)-tyrosine kinase inhibitors (TKIs) in non-small cell lung amplification, but not with K-Ras mutation. MET amplification may cancer (NSCLC) have raised hopes that targeting other deregulated identify a subset of NSCLC for new targeted therapy. It will also be growth factor signaling, such as the hepatocyte growth factor/MET important to evaluate MET copy number to properly interpret future pathway, will lead to new therapeutic options for NSCLC. Further- clinical trials. more, NSCLC present secondary EGFR-TKIs resistance related to Key Words: Non-small cell lung cancer, EGFR gene, MET gene, exons 20 and 19 EGFR mutations or more recently to MET ampli- K-Ras gene. fication. The aim of this
Journal of Thoracic Oncology – Wolters Kluwer Health
Published: Apr 1, 2008
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.